Leyuan Xu, PhD
Assistant ProfessorCards
About
Research
Publications
2024
VCAM-1 mediates proximal tubule-immune cell crosstalk in failed tubule recovery during AKI-to-CKD transition
Melchinger I, Guo K, Li X, Guo J, Cantley L, Xu L. VCAM-1 mediates proximal tubule-immune cell crosstalk in failed tubule recovery during AKI-to-CKD transition. American Journal Of Physiology. Renal Physiology 2024 PMID: 39116349, DOI: 10.1152/ajprenal.00076.2024.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseVCAM-1 expressionProximal tubule cellsVCAM-1Tubule cellsKidney Precision Medicine ProjectProinflammatory cytokinesAcute kidney injury to chronic kidney diseaseModel of chronic kidney diseaseExpression of vascular cell adhesion protein 1Cell adhesion pathwaysInflammatory response to injuryInjured proximal tubule cellsVascular cell adhesion protein 1Mouse model of chronic kidney diseaseRisk of progressionChronic kidney disease transitionIncreased immune cell adhesionVCAM-1-positive cellsOverexpression of VCAM-1Inhibition of NF-kB signalingActivation of NF-kBImmune cell adhesionSingle-cell transcriptome analysisRAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
Li B, Jin K, Liu Z, Su X, Xu Z, Liu G, Xu J, Chang Y, Wang Y, Zhu Y, Xu L, Wang Z, Liu H, Zhang W. RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer. Journal Of Immunotherapy 2024 PMID: 38800996, DOI: 10.1097/cji.0000000000000525.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerPD-L1 blockadePlatinum-based chemotherapyPD-L1Zhongshan HospitalBladder cancerProgrammed cell death ligand 1Muscle-invasive bladder cancer patientsResponse to platinum-based chemotherapyEfficacy of platinum-based chemotherapyCell death ligand 1DNA damage repairPD-L1 inhibitorsDeath-ligand 1Tumor immune contexturePredictive efficacyGenomic instabilityIMvigor210 cohortImmune contextureChemotherapeutic responseTherapeutic responseClinical benefitRetrospective studyClinical valueTherapeutic guidanceIntegration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Liu H, Chang Y, Zhu Y, Xu L, Wang Z, Wang Y, Zhang W. Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer. Cancer Science 2024, 115: 1306-1316. PMID: 38402640, PMCID: PMC11007017, DOI: 10.1111/cas.16119.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerImmune checkpoint blockadeCombination of immune checkpoint blockadeCD4<sup>+</sup> T cellsFibroblast growth factor receptor 3T cellsZhongshan HospitalMolecular subtypesBladder cancerMuscle-invasive bladder cancer patientsResponses to FGFR inhibitorsCD4+ T cellsPD-L1 blockadeImmune suppressive microenvironmentTransforming growth factor-bGrowth factor BIMvigor210 cohortCheckpoint blockadePD-L1Clinical responseSuppressive microenvironmentImmune microenvironmentImmunotherapeutic responseChemotherapeutic responseClinical outcomesTP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma
Jin K, Xu J, Su X, Xu Z, Li B, Liu G, Liu H, Wang Y, Zhu Y, Xu L, Zhang W, Liu Z, Wang Z, Chang Y, Xu J. TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma. The Journal Of Pathology 2024, 263: 139-149. PMID: 38380548, DOI: 10.1002/path.6266.Peer-Reviewed Original ResearchPD-1/PD-L1TP53 mutationsOverall survivalUrothelial carcinomaGenetic alterationsClinical significance of TP53 mutationsPD-1/PD-L1 blockade therapyCD8<sup>+</sup> T cell infiltrationIncreased CD8<sup>+</sup> T cell infiltrationElevated tumor mutation burdenSignificance of TP53 mutationsPD-1/PD-L1 blockadeTP53 disruptive mutationsInflamed tumor microenvironmentPlatinum-based chemotherapyT cell infiltrationTumor immune microenvironmentTumor mutational burdenWild-type TP53P53 protein functionTP53 mutation statusSensitive to immunotherapyHeterogeneous clinical outcomesPoorer overall survivalImprove risk stratificationPOLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Chang Y, Wang Y, Zhu Y, Xu L, Xu J, Wang Z, Liu H, Zhang W. POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1. Cancer Medicine 2024, 13: e6962. PMID: 38457207, PMCID: PMC10922026, DOI: 10.1002/cam4.6962.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerProgrammed cell death ligand 1Immune checkpoint blockadeTumor mutational burdenImmune microenvironmentZhongshan HospitalBladder cancerInfiltration of immune effector cellsEfficacy of immune checkpoint blockadePOLQ expressionCell death ligand 1High tumor mutational burdenChromosomal instabilityActive tumor immune microenvironmentAntitumor immune microenvironmentDeath-ligand 1Efficacy of immunotherapyPlatinum-based chemotherapyTumor immune microenvironmentSensitivity to chemotherapyImmune effector cellsProduction of neoantigensIMvigor210 cohortCheckpoint blockadePD-L1Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
Su X, Jin K, Guo Q, Xu Z, Liu Z, Zeng H, Wang Y, Zhu Y, Xu L, Wang Z, Chang Y, Xu J. Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer. British Journal Of Cancer 2024, 130: 852-860. PMID: 38212482, PMCID: PMC10912081, DOI: 10.1038/s41416-023-02572-9.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerImmune checkpoint blockadeResponse to ICBResponse to platinum-based chemotherapyPlatinum-based chemotherapyPD-L1Bladder cancerZhongshan HospitalPD-1/PD-L1 blockadePD-1/PD-L1Cox regression analysisKaplan-Meier survivalCheckpoint blockadeCDK6 expressionResponse scoresImmune microenvironmentTherapy responseClinical outcomesPoor prognosisCancer Genome AtlasClinical significanceChemotherapyClinical relevanceProgression of cell cycleCancer treatmentIntegrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer
Li B, Jin K, Liu Z, Su X, Xu Z, Liu G, Xu J, Liu H, Chang Y, Wang Y, Zhu Y, Wang Z, Xu L, Zhang W. Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer. Cancer Immunology, Immunotherapy 2024, 73: 66. PMID: 38430246, PMCID: PMC10908619, DOI: 10.1007/s00262-024-03651-3.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerCD8+ T cell infiltrationT cell infiltrationMolecular subtypesBladder cancerEfficacy of antitumor responseElevated tumor mutation burdenPositive response to immunotherapyCD8+ T cellsPD-L1 expressionResponse to immunotherapyTumor mutational burdenResponse to chemotherapyOverall survival outcomesSubtype-specific treatmentAntitumor responsePD-L1Intrinsic subtypesMutational burdenZhongshan HospitalSurvival outcomesT cellsTreatment responseResultsAmong patientsCancer Genome Atlas
2023
Analysis of the human kidney transcriptome and plasma proteome identifies markers of proximal tubule maladaptation to injury
Wen Y, Su E, Xu L, Menez S, Moledina D, Obeid W, Palevsky P, Mansour S, Devarajan P, Cantley L, Cahan P, Parikh C, Project K, Injury T. Analysis of the human kidney transcriptome and plasma proteome identifies markers of proximal tubule maladaptation to injury. Science Translational Medicine 2023, 15: eade7287. PMID: 38091407, DOI: 10.1126/scitranslmed.ade7287.Peer-Reviewed Original Research
2022
Integration of Human Kidney Transcriptome and Plasma Proteome Identifies Novel Biomarkers of Proximal Tubule Maladaptation to Injury
Wen Y, Su E, Xu L, Menez S, Moledina D, Palevsky P, Cantley L, Cahan P, Parikh C. Integration of Human Kidney Transcriptome and Plasma Proteome Identifies Novel Biomarkers of Proximal Tubule Maladaptation to Injury. Journal Of The American Society Of Nephrology 2022, 33: 358-358. DOI: 10.1681/asn.20223311s1358b.Peer-Reviewed Original ResearchImmune-Mediated Tubule Atrophy Promotes AKI to CKD Transition
Xu L, Guo J, Moledina D, Cantley L. Immune-Mediated Tubule Atrophy Promotes AKI to CKD Transition. Journal Of The American Society Of Nephrology 2022, 33: 872-872. DOI: 10.1681/asn.20223311s1872b.Peer-Reviewed Original Research
Academic Achievements and Community Involvement
Links & Media
News
- February 15, 2023
Discoveries & Impact (February 2023)
- December 02, 2021
Yale Scientists Seek to Shift Treatment of Kidney Damage
- January 13, 2021
Discoveries & Impact (January 2021)
- September 16, 2019
2019 Department of Internal Medicine Faculty Appointments and Promotions